Zidesamtinib Shows High Response Rate in ROS1-Positive Lung Cancer
Updated trial data showed a 94% objective response rate with zidesamtinib in TKI-naive patients with advanced ROS1-positive non-small cell lung cancer. Complete responses occurred in 15% of patients, and all 10 evaluable patients with brain metastases had intracranial responses. The findings support a planned application to expand the drug's approval to first-line use.
Zidesamtinib already carries FDA approval for previously treated advanced ROS1-positive NSCLC, and the ARROS-1 trial enrolled 629 participants across North America, Europe, and Asia Pacific. The agent was specifically designed to overcome limitations of existing frontline TKIs, including weak central nervous system activity and troublesome side effects, while limiting TRK inhibition.
In the safety population of 532 patients, peripheral edema (34%) and weight gain (18%) were the most frequent treatment-related adverse events. The efficacy results compare favorably with taletrectinib and repotrectinib, two TKIs currently used in clinical practice for TKI-naive patients with this malignancy.
This data could reshape first-line treatment for ROS1-positive NSCLC, offering patients a therapy with unusually high response rates and robust intracranial activity. The 94% objective response rate and absence of CNS progression events may reduce reliance on whole-brain radiation, preserving quality of life. If approved for first-line use, zidesamtinib could become a standard option, though longer follow-up is needed to confirm durability and long-term tolerability.